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As the life expectancy of patients with cystic ﬁbrosis (CF) improves, treatment related morbidity is
increasingly recognised. Totally implantable venous access devices (TIVADs) offer reliable long term
central venous access but are associated with recognised complications including venous thrombosis.
Superior vena cava obstruction (SVCO) however has been rarely reported in this setting. We report
a single CF centre’s experience of SVCO associated with TIVADs in patients with CF, followed by a review
of the published literature on risk factors, preventative strategies and treatment approaches.
 2011 Elsevier Ltd. All rights reserved.1. Educational aims
The educational aims of this manuscript are to
 Highlight various clinical presentations of TIVAD associated
SVCO
 Discuss strategies for prevention of TIVAD associated SVCO
 Discuss strengths and weakness of the diagnostic and treat-
ment modalities available for treatment of TIVAD associated
SVCO.2. Introduction
People with cystic ﬁbrosis (CF) require frequent treatment with
parenteral antibiotics for infective exacerbations of the associated
bronchiectasis. Recurrent venous cannulationmaybe complicated by
thrombosis of peripheralveins,whicheventually limitsvenousaccess
options. Totally implantable venous access devices (TIVADs) offer
long term central venous access, but theymayalso be complicated by
infection and thrombosis. TIVAD associated venous thrombosis rates
between 0 and 13.6% have been reported (Table 1),1e11 but superior0 277 206 (mobile); fax: þ61
(D. Smith).
rved.vena cava obstruction (SVCO) is a very rare occurrence.3e5,8,11,12 We
present the largest case series to date of TIVAD associated SVCO, in
patients with CF, and discuss possible risk factors, preventative
strategies, and treatment approaches.
3. Case series
Between February 2008 and December 2009 sixty (24%) of the
251 patients attending our adult CF centre had a TIVAD in situ and
during this period ﬁve individuals (8%) developed symptomatic
SVCO (Table 2). In four patients the TIVAD had been inserted at
another hospital (2 overseas general surgical units, 1 paediatric CF
centre, 1 interstate hospital), which employ different insertion
techniques and catheter types to our own practice. The cases are
discussed in greater detail to highlight important clinical features
and potential management strategies.
3.1. Case 1
A 16 year old female, with severe lung disease presented with
facial swelling and worsening breathlessness 19 months after the
insertion of her third TIVAD (2 removed previously; 1 suspected
infection, 1 blocked). Initial colour ﬂow Doppler ultrasound (CDUS)
demonstrated normal compressible upper extremity veins.
However, due to ongoing symptoms computed tomography
venography (CTV) was performed which demonstrated occlusive
Table 1
TIVAD related venous thrombosis rates in patients with CF published over the last 20 years.
Study No. of TIVADs Duration of follow-up No. of symptomatic Thromboses No. of episodes of SVCO Anticoagulated Thrombolysed
Royle et al.1 165 20 years 5 (3%) 0 5 5
Munck et al.2 452 8 years 21 (4.7%) N/R N/R N/R
Aitken and Tonelli3 85 10 years 14 (16%) 2 8 0
Kariyawasam et al.4 115 13 years 4 (3.5%) 3 4 0
Deerojanawong et al.5 57 9 years 5 (9%) 1 5 5
Rodgers et al.6 61 8 years 4 (7%) 0 4 3
Burdon et al.7 75 5 years 0 (0%) 0 0 0
Sola et al.8 22 6 years 3 (14%) 3 0 0
Yung et al.9 33 8 years 3 (9%) 0 3 1
Morris et al.10 68 4 years 0 0 0 0
Garwood et al.11 47 12 years 3 (6%) 3 0 0
Total 1180 62 (5%) 12 (1%)
TIVAD: Totally implantable venous access device; SVCO: superior vena cava obstruction, N/R: not reported.
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SVC (Fig. 1a). Endovascular thrombus aspirationwas attempted, but
abandoned due to severe coughing. She was transferred to the
intensive care unit and underwent TIVAD directed thrombolysis
with alteplase, an initial bolus of 2.5 mg was administered, fol-
lowed by an infusion of 0.5 mg/h over a 72 h period. Her gas
exchange and cardiovascular status remained stable throughout
the infusion. Thrombolysis resulted in total symptomatic resolu-
tion. A repeat CTV demonstrated partial recannulisation of the SVC,
with no evidence of secondary pulmonary emboli (Fig. 1b). Thera-
peutic anticoagulation with warfarin (target INR 2.0e3.0) was
commenced. The TIVAD was removed after six months due to
intermittent blockage, and a new left sided chest TIVAD inserted.
Anticoagulation was continued without complication up to the
patient’s death six months later due to respiratory failure.
3.2. Case 2
A 23 year old female, with a right sided chest TIVAD in situ for 7
years was admitted for an elective surgical procedure. She was
using depo provera contraception. On initiation of preoperative
intravenous hydration she developed upper limb and facial
swelling. Digital subtraction venography (DSV) demonstrated
thrombus around the catheter obstructing the SVC. A portagram
revealed normal ﬂow through the catheter. Magnetic resonance
venography (MRV) conﬁrmed thrombus extending along the bra-
chiocephalic vein to conﬂuence of SVC. Surgery under general
anaesthesia was performed without complication and intravenous
heparinisation was commenced immediately post-operation, fol-
lowed by therapeutic anticoagulation with warfarin. After three
months, the warfarin was discontinued due to persistent, small
volume haemoptyses. Nine months later she developed increasing
symptoms of severe facial plethora and headaches on coughing.
Repeat MRV demonstrated worsening focal obstruction of the SVC.
The TIVAD was removed and balloon angioplasty of the SVC per-
formed with good symptomatic response. To provide ongoing
intravenous access a new TIVAD was inserted surgically in the
inferior vena cava (IVC). Six months later the patient underwent
lung transplantation, intra-operatively the SVC was found to be
cicatrized with marked narrowing, but no thrombosis. The SVC was
refashioned with a pulmonary artery allograft with an excellent
symptomatic response.
3.3. Case 3
A 31 year old female who had a TIVAD inserted at an interstate
hospital, presented to the same hospital nine months later with
acute pancreatitis and dehydration. On initiation of intravenousﬂuids, she developed symptoms of throat tightness, accompanied
by facial and upper limb swelling. She had commenced the oral
contraceptive pill (OCP) twomonths prior to presentation. DSV and
a portagram demonstrated reduced line patency with narrowing of
the SVC distal to the catheter tip. Anticoagulation with heparin
(7 days) followed by warfarin was commenced. The line was left in
situ. On admission to our centre four months later for elective
cholecystectomy, she continued to experience signiﬁcant symp-
toms of SVCO. MRV demonstrated a high grade stenosis of the SVC
(max diameter of 4 mm) (Fig. 2a). Balloon angioplasty was per-
formed followed by TIVAD removal. Two months later she had
continued and substantial improvement in symptoms and a repeat
MRV demonstrated improved patency of the SVC (max diameter of
10 mm) (Fig. 2b).
3.4. Case 4
An 18 year old female presented with an infective exacerbation
of CF and dehydration two weeks following a 4 h ﬂight from New
Zealand to Australia. A TIVAD had been inserted in New Zealand
three months prior to presentation. She had also commenced the
OCP three weeks prior to presentation. On initiation of intravenous
rehydration she developed facial swelling and throat tightness. CTV
demonstrated the TIVAD tip to be located at the conﬂuence of the
brachiocephalic vein, with adherent clot extending distally, and
almost complete occlusion of the mid SVC (Fig. 3a). Anticoagulation
was immediately commenced with IV heparin followed by
warfarin. Serial CTV’s over the next four months demonstrated
progressive reduction in clot size (Fig. 3b) and the TIVAD was then
removed without complication with cessation of warfarin. Twelve
months following TIVAD removal the patient remains asymptom-
atic. When requiring intravenous access a mid-line peripheral
catheter has been inserted under ultrasound guidance with the tip
positioned in the axillary vein and removed at the end of each
hospitalisation.
3.5. Case 5
A 31 year old female who had had a left sided TIVAD inserted
nine months previously (right sided insertion not technically
possible) was noted by her carer to have developed prominent
collateral veins on her anterior chest wall. She had a background
history of moderate lung disease, epilepsy, and intellectual
impairment. A CTV revealed left subclavian vein narrowing with
catheter tip associated thrombus in the SVC. Given the absence of
symptoms and previous difﬁculty obtaining venous access the
TIVAD was left in situ. Prophylactic warfarin was commenced (INR
range 1.5e2.0). Currently, ﬁve months later the TIVAD continues to
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D. Smith et al. / Respiratory Medicine CME 4 (2011) 99e104 101function satisfactorily and she remains asymptomatic with no
bleeding complications.
4. Discussion
To our knowledge this is the largest reported series of SVCO
associated with TIVADs in patients with CF.
The explanation for the higher incidence of SVCO compared to
previously reported series is not immediately apparent. Post-
insertion care and maintenance of TIVADs at our centre is in line
with that of other large CF centres worldwide. It is noteworthy that
three of the TIVADs were inserted in other hospitals that perform
this procedure infrequently, raising the possibility that operator
experience may be a contributory factor. Given the year long high
ambient temperatures in Queensland (in Brisbane the annual mean
maximum temperature is 26.5 C, and mean minimum tempera-
ture is 16.2 C)13 there is a high risk of dehydration in patients with
CF, which may increase the risk of thrombosis in this particular
population. It is also noteworthy that all ﬁve of the patients in the
case series were female and three of them were on some form of
hormonal contraception. Finally it is possible that previous authors
may have mis-classiﬁed SVCO as symptomatic thrombosis.
The cases highlight a number of important lessons in the
prevention, diagnosis, and treatment of catheter associated SVCO
and potentially represents another important morbidity associated
with increased life span for adults with CF.
4.1. Risk factors for thrombosis
4.1.1. Oral contraceptives
The OCP is associated with spontaneous deep vein and upper
extremity thrombosis,14 and is likely to increase the risk of central
line related thrombosis. The risk may be lessened but not amelio-
rated with progesterone only pills. The World Health Organisation
(WHO) guidelines on contraception state that systemic oestrogen-
based contraception poses an unacceptable health risk in people
who have previously suffered venous thrombo-embolism, as well
as in those with an ongoing increased thrombogenic risk (a cate-
gory into which patients with TIVADs may arguably be included).
The WHO favours the use of intrauterine devices (either copper or
drug eluting), barrier devices, or progesterone only pills in this
circumstance.15
4.1.2. Line related factors
Correct catheter placement is important in reducing the risk of
thrombosis. In a previously reported series of 379 patients with
a TIVAD for cancer chemotherapy,16 ten episodes of venous
thrombosis occurred. In nine of these cases, the catheter tip was
positioned in the upper one-third of the SVC and 50% had evidence
of SVC narrowing on the plain chest radiograph. These ﬁndings
were replicated in a prospective study which demonstrated
a thrombosis rate of 46% for correctly versus 6% for incorrectly
inserted catheters.17 Local endothelial trauma by the catheter tip
may predispose to thrombus formation, but other factors may
include; the catheter material (polyurethane catheters being found
to be the least thrombogenic compared to silicone, polyethylene, or
Teﬂon coated lines); catheter diameter (greater risk with larger
diameter); and catheter placement in the left subclavian vein
because of the more acute anatomical course into the SVC.2,16
4.1.3. Thrombophilia
There are two published studies on the rate of thrombophilia in
patients with CF. Both studies reported that patients with CF have
higher rates of thrombophilia on testing than control pop-
ulations.18,19 The authors therefore recommended thrombophilia
Fig. 1. CT images of case 1: a) complete obstruction of the SVC at the tip of the TIVAD with intra-luminal thrombus (black arrow), and collateral ﬂow in the azygous vein (white
arrow); b) recannulisation following TIVAD directed thrombolysis.
D. Smith et al. / Respiratory Medicine CME 4 (2011) 99e104102screening prior to TIVAD insertion, although neither study actually
demonstrated any correlation with the prevalence of line associ-
ated thrombosis.
These recommendations need to be viewed with caution, as
thrombophilia testing abnormalities in CF are often transient and
related to the acute phase response, similar to the abnormalities
observed in anti-phospholipid antibody and protein C levels in
some CF patients when unwell.19
4.1.4. Dehydration
Dehydration can be a major problem in patients with CF, espe-
cially during infective exacerbations in sub-tropical and tropical
climates. The associated haemoconcentration may represent
a signiﬁcant risk factor for venous thrombosis.20
4.1.5. Author’s practice
We counsel female patients on the risks associated with
systemic hormone based contraceptive prior to TIVAD insertion
and observe the WHO recommendations where possible by
switching patients from systemic oestrogen-based contraception.
Our centre currently inserts small diameter (8 French), poly-
urethane TIVAD catheters. Depending on the preferred location of
the injection port these may be inserted surgically (chest) or
radiologically (arm), with the catheter tip sitting in the lower one-
third of the SVC. In the absence of a family history of thrombosis weFig. 2. MRI images of case 3: a) tight stenosis in the mid SVC (white arrow); b) follow-udo not perform routine thrombophilia screening prior to TIVAD
insertion. Patients with TIVADs are aggressively rehydrated when
admitted for treatment of exacerbations or elective surgery.4.2. Investigation of SVC obstruction
A number of imaging modalities are available for the investi-
gation of SVCO.
4.2.1. Colour ﬂow Doppler ultrasound
Sensitivity and speciﬁcity rates of 94% and 96% respectively have
been reportedwith CDUS for the diagnosis of symptomatic catheter
related upper extremity venous thrombosis.21 This accuracy,
combined with its safety and wide availability, makes CDUS the
investigation of ﬁrst choice. However, as highlighted in case 1, CDUS
can produce false negatives due to difﬁculty in obtaining suitable
acoustic windows to visualise the SVC, and should not be consid-
ered sufﬁcient on its own to exclude thrombosis when clinical
suspicion is high.
4.2.2. Digital subtraction venography
DSV is the gold standard for assessing upper extremity throm-
bosis and is widely available in most radiological departments.
However, it is of limited use in up to 20% of cases due to difﬁcultyp scan two months following balloon dilatation showing ongoing good resolution.
Fig. 3. CT images of case 4: a) TIVAD inserted via left subclavian vein with the tip sitting high in the SVC (arrow) with adherent thrombus obstructing the SVC; b) resolution of
thrombus with four months of anticoagulation.
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oedema), and the small risk of contrast allergy. The other draw-
backs of DSV are the need to perform bilateral venopunctures to
completely map the upper extremity vasculature, and failure to
visualise the internal jugular vein.
4.2.3. Computed tomography venography and magnetic resonance
venography
CT and MRI based techniques have the advantage of imaging the
entire upper extremity vasculature in one scan sessionwhich allows
assessment of the site of obstruction and planning of future potential
vascular access sites. Multi-slice detector CT scanners provide rapid
image acquisition and excellent resolution of the intravascular
thrombus and the degree of vessel stenosis, when compared to
conventional CT scans.22 The major limitation of CT imaging is the
requirement for IV contrast and radiation exposure.
Both non-contrast and gadolinium enhanced MRV have been
shown to be sensitive in detecting SVC obstruction. Gadolinium
enhancement provides the advantages of faster image acquisition
and less artefact.23 However gadolinium nephrotoxicity limits its
use in patients with renal impairment.24 Techniques currently in
development may allow signiﬁcant gadolinium dose reduction and
wider applicability.23 A major limitation of MRV is its limited
availability outside of major radiology centres.
4.2.4. Authors practice
We base our choice of imaging modality on the individual case
presentation. Where endovascular procedures are considered we
favour the use of MRV. We recommend that if clinical suspicion of
SVCO is high that a normal CDUS is not considered sufﬁcient to
exclude the diagnosis.4.3. Prophylaxis and treatment of thrombosis
Prospective studies into the optimum management of line
related thrombosis are limited, with the majority of recommen-
dation based on small numbers of studies or extrapolated from
studies in patients with cancer.
4.3.1. Prophylactic antiplatelet/anticoagulation therapy
Following a retrospective audit of TIVAD complications in
patients with CF which demonstrated a thrombosis rate of 13.6%
Sola et al. recommended a policy of initiating all patients with
a TIVAD on aspirin, however the authors have not reported theimpact on rates of thrombosis.16 There is low level evidence avail-
able that suggests low dose anticoagulation is beneﬁcial in pre-
venting line related thrombosis in patients with cancer,25 however
there are no similar studies published in patients with CF.
The potential risk of routine anticoagulation in CF is haemopt-
ysis. The rate of massive haemoptysis in patients with CF is
approximately 1 per 100 patient years 26 and most often occurs in
patients with severe lung function impairment (the patient group
most likely to require a TIVAD) and is associated with increased
decline in lung function and mortality.26
4.3.2. Therapeutic anticoagulation
The optimum treatment protocol for catheter related throm-
bosis remains controversial. Guidelines published by The American
College of Chest Physicians (ACCP) recommend that patients should
be anticoagulated for a 3e5 day period initially with heparin, fol-
lowed by removal of the line if it is no longer required and three
months of anticoagulation.27 Where ongoing venous access is
required they recommend that the line may remain in situ, but that
a longer period of anticoagulation should be considered, although
this may be reduced to prophylactic doses after the initial three
months.28
4.3.3. Thrombolysis
Catheter directed thrombolysis has been shown to effectively
restore vessel patency if delivered early after clot development but
studies have been limited to very small numbers of patients, and
varied in thrombolytic regimen employed. Thrombolysis has not
been shown to be superior to anticoagulation alone in the longer
term.29 The ACCP therefore recommends that thrombolysis be
limited to those with recent onset of severe symptoms and only be
undertaken in centres with adequate expertise.27
4.3.4. Endovascular and surgical intervention
There are no prospective trials comparing endovascular proce-
dures to medical therapy in benign SVCO. A benign cause was
identiﬁed in 14 of 82 patients included in a series of patients treated
with endovascular stenting for persistent SVCO despite medical
treatment. All 14 were successfully treated, with no reported
complications, however six required a second endovascular
procedure during the follow-up period.30 There have, however
been case reports of stent migration with associated morbidity and
mortality.31 Endovascular clot retrieval has been reported to be
successful in isolated case reports only. The ACCP recommend that
endovascular procedures only be performed in specialised centres
D. Smith et al. / Respiratory Medicine CME 4 (2011) 99e104104and only in selected cases where conservative treatment has
failed.27
Rizvi et al. compared endovascular stenting to surgical recon-
struction in 70 patients with severe, symptomatic SVCO despite
anticoagulation. Surgical reconstruction was associated with
signiﬁcant morbidity, and the authors advocated stenting as the
preferred therapeutic option.32
4.3.5. Authors practice
There is currently no data to support the role of prophylactic
anticoagulation and we therefore do not initiate this routinely.
Following symptomatic thrombosis, we initiate therapeutic anti-
coagulation with warfarin (INR 2e3) for three months, followed by
low dose warfarin (INR 1.5e2.0) while the TIVAD remains in situ.
TIVAD removal is considered for ongoing signiﬁcant symptoms of
SVCO, or when signiﬁcant bleeding necessitates premature
discontinuation of anticoagulation. Thrombolysis and angioplasty
is considered in severely symptomatic patients and is carried out
with intensive care support. Although primary surgical recon-
struction is not advocated, in the second case the authors highlight
a novel surgical approach that was only possible at the time of lung
transplantation.
5. Conclusion
The TIVAD offers reliable long term venous access for patients
with CF who require repeated courses of intravenous antibiotics,
especially in patients with limited peripheral access options. To
minimize complications, expertise in line insertion and mainte-
nance is paramount. There remains limited evidence to guide
clinicians in important management issues including thrombo-
philia screening and prophylactic anticoagulation, andmulti-centre
randomised controlled trials to address these issues would be
beneﬁcial.
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